Lab Information

Elena Netchiporouk (MD/MSc)

Scientist
Centre for Translational Biology
Department of Medicine (McGill)

Research Profile

 Fundamental: 50%
 Clinical: 20%
 Epidemiology: 30%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Chronic spontaneous urticaria • scleroderma • morphea • systemic sclerosis • skin fibrosis

Research Interests

The incidence of autoimmune diseases affecting the skin and/or internal organs is rising steadily, but at a rate that cannot be explained by genetics alone. This argues for the importance of environmental causes in disease initiation and, possibly, progression. Pollutants and microorganisms (e.g., viruses) may directly damage our cells and elicit production of auto-antibodies by our immune system against our own cells. My research program focuses on understanding the interaction between environment and autoimmune diseases affecting the skin, specifically chronic urticaria and systemic sclerosis. While both are autoimmune in nature, they are completely different with respect to their clinical presentation and prognosis, which makes them ideal to study in parallel.


Team Members

Name Position

Latest Publications

  1. Zhu, C., Fein, M., Ben-Shoshan, M., Iannattone, L. & Netchiporouk, E. (2024). Successful Treatment of Chronic Spontaneous Urticaria using Tralokinumab: A Case Report. Clinical and experimental dermatology.
  2. BinJadeed, H., Huang, H. Z., Joly-Chevrier, M., Javed, G. & Netchiporouk, E. (2024). Favorable Response to Type 2 Inhibitors in Patients With Darier Disease. JAMA dermatology, vol. 160, p. 1007-1009.
  3. Muntyanu, A., Aw, K., Kaouache, M., Rahme, E., Osman, M., Baron, M., Ghazal, S. & Netchiporouk, E. (2024). Epidemiology of systemic sclerosis in Quebec, Canada: a population-based study. Lancet regional health. Americas, vol. 35, p. 100790.
  4. Moussa, S., Ouchene, L., Udupa, M., BinJadeed, H., Bashihab, R., Litvinov, I., Foulkes, W. D. & Netchiporouk, E. (2024). Evoked Piloerection Sign/Pseudo-Darier Sign: a Clinical Clue to the Diagnosis of Cutaneous Leiomyomas. Journal of the American Academy of Dermatology, vol. 91, p. 735-737.
  5. Ghazal, S., Zhang Huang, H., Gabrielli, S., Khoury, L., Pehr, K., Veilleux, M., Chédeville, G., McCuaig, C., Piram, M. & Netchiporouk, E. (2024). Localized Scleroderma Burden: A Scoping Review Focusing on the Health-Related Quality of Life, Mental Health, and Productivity. Journal of cutaneous medicine and surgery, p. 12034754241260018.
  6. Le, M., Zhu, C. K., Perlman, L., Gabrielli, S., Netchiporouk, E., Nguyen, A., Zhang, X., Ensina, L. F. & Ben-Shoshan, M. (2024). Prevalence of Atopic Conditions in Children with Chronic Urticaria. The journal of allergy and clinical immunology. In practice, vol. 12, p. 2534-2536.e2.
  7. El-Sayes, Y., Joly-Chevrier, M., BinJadeed, H., Litvinov, I. V. & Netchiporouk, E. (2024). Epidermal Growth Factor Receptor Inhibitors Induced Skin Toxicities - Zinc Supplementation to the Rescue?. Journal of the American Academy of Dermatology, vol. 91, p. e69-e71.
  8. Zhu, C., BinJadeed, H., Gabrielli, S., Prosty, C., Rahme, E., Shand, G., Fein, M., Ben-Shoshan, M. & Netchiporouk, E. (2024). Prevalence of omalizumab resistant chronic urticaria and real world effectiveness of dupilumab in omalizumab refractory chronic urticaria patients: a single center experience. Clinical and experimental dermatology, vol. 49, p. 1227-1231.
  9. Ouchene, L., Wilde, B., Chan-Pak-Choon, F., Camacho Valenzuela, J., Brimo, F., Witkowski, L., Christofk, H., Domecq, C., Fu, L., Weber, E., Lemieux Anglin, B., Netchiporouk, E. & Foulkes, W. D. (2024). Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic. Genes, chromosomes & cancer, vol. 63, p. e23221.
  10. Le, M., Khoury, L., Lu, Y., Prosty, C., Cormier, M., Cheng, M. P., Fowler, R., Murthy, S., Tsang, J. L. Y., Ben-Shoshan, M., Rahme, E., Golchi, S., Dendukuri, N., Lee, T. C. & Netchiporouk, E. (2024). COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial. Open forum infectious diseases, vol. 11, p. ofae102.
More on PubMed 



See also

Card image
Moshe
Ben-Shoshan


See profile
Card image
Carolyn
Jack


See profile
Card image
Christian
Pineau


See profile
Card image
Waqqas
Afif


See profile
Card image
Todd
Lee


See profile
Card image
Matthew
Cheng


See profile